
1. vaccine. 2016 jun 24;34(30):3435-40. doi: 10.1016/j.vaccine.2016.05.013. epub
2016 may 18.

emergency deployment genetically engineered veterinary vaccines europe.

ramezanpour b(1), de foucauld j(2), kortekaas j(3).

author information: 
(1)vrije universiteit amsterdam, athena institute, de boelelaan 1085, 1081 hv
amsterdam, netherlands.
(2)ceva santé animale, 10 avenue de la ballastière, 33500 libourne, france.
(3)department virology, central veterinary institute (cvi-lelystad), part of
wageningen university research centre, p.o. box 65, 8200 ab lelystad, the
netherlands. electronic address: jeroen.kortekaas@wur.nl.

on 9th november 2015, preceding world veterinary vaccine congress, a
workshop held discuss veterinary vaccines deployed rapidly
to appropriately respond future epizootics europe. considering their
potential unprecedented suitability surge production, workshop
focussed vaccines based genetically engineered viruses replicon
particles. workshop attended academics representatives from
leading pharmaceutical companies, regulatory experts, european medicines
agency european commission. outline present regulatory
pathways genetically engineered vaccines europe describe incentive
for organization pre-congress workshop. participants agreed that
existing european regulations deliberate release genetically engineered
vaccines environment updated facilitate quick deployment of
these vaccines emergency situations.

copyright © 2016.

doi: 10.1016/j.vaccine.2016.05.013 
pmid: 27208587  [indexed medline]

